Status: Recruiting

Brief Summary:

A phase 2b study to assess the safety and efficacy of a Posterior Segment Drug Delivery System (DDS) with Brimonidine in patients with geographic atrophy GA

Main inclusion criteria:

  1. Multifocal lesions located outside a 300μm radius the fovea
  2. At least one focal lesion ≥ 0.2 mm2
  3. The total lesion area 1.25mm2 – 18mm2
  4. Banded or diffuse perilesional hyper-auto fluorescence evident on auto fluorescence
  5. The distance between the optic disc or PPA and any atrophic lesion must be >300μm
  6. Presence of ≥ 5 reticular drusen
  7. BCVA ≥ 20/125
  8. Fellow eye BCVA > 20/200

Exclusion criteria:

  1. History or evidence of CNV in either eye
  2. -6 diopters of myopia or worse
  3. Diabetic retinopathy